Stock 600750 JIANG ZHONG PHARMACEUTICAL CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Jiang Zhong Pharmaceutical Co.,Ltd

Equities

600750

CNE000000M80

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
26.77 CNY -0.34% Intraday chart for Jiang Zhong Pharmaceutical Co.,Ltd -4.22% +28.21%
Mar. 25 Jiang Zhong Pharmaceutical Co.,Ltd Proposes Cash Dividend CI
Mar. 22 Jiang Zhong Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The group's high margin levels account for strong profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Analyst opinion has improved significantly over the past four months.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • In relation to the value of its tangible assets, the company's valuation appears relatively high.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
JIANG ZHONG PHARMACEUTICAL CO.,LTD Stock Jiang Zhong Pharmaceutical Co.,Ltd
+28.21% 2.3B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.72% 566B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.72% 231B
B+
NOVARTIS AG Stock Novartis AG
+5.24% 200B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-8.75% 195B
A+
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
-
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 600750 Stock
  4. Ratings Jiang Zhong Pharmaceutical Co.,Ltd